Bevacizumab in recurrent WHO grades II–III glioma

PURPOSE: The management of recurrent WHO grades II–III (rGII–III) glioma is not well established. This study describes the clinical outcomes in patients who received bevacizumab as rescue treatment. METHODS: In this retrospective study, the main inclusion criteria were as follows: adult patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Annakib, Soufyan, Rigau, Valérie, Darlix, Amélie, Gozé, Catherine, Duffau, Hugues, Bauchet, Luc, Jarlier, Marta, Fabbro, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391542/
https://www.ncbi.nlm.nih.gov/pubmed/37534252
http://dx.doi.org/10.3389/fonc.2023.1212714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391542/
https://www.ncbi.nlm.nih.gov/pubmed/37534252
http://dx.doi.org/10.3389/fonc.2023.1212714

Ejemplares similares